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Abstract 
The objective of the present work was to enhance the solubility and 
dissolution rate of valsartan (VAL) a poorly water soluble antihypertensive, 
by spherically agglomerated solid dispersions using methanol, water and 
dichloromethane as good solvent, poor solvent and bridging liquid, 
respectively. The hydrophilic polymers like polyvinyl pyrrolidone, 
Hydroxypropyl β-cyclodextrin, Hydroxypropyl methylcellulose were used in 
agglomeration process. The pure drug (VAL) and its agglomerates with 
different polymers were characterize by differential scanning calorimetry 
(DSC), X-ray diffraction (XRD), IR spectroscopic studies and scanning 
electron microscopy (SEM). The DSC results indicated that decrease in 
melting enthalpy related to disorder in the crystalline content. XRD studies 
also showed changes in crystallanity, IR spectroscopy revealed that there 
were no chemical changes in the recrystallized agglomerates. The spherically 
agglomerated solid dispersions with different polymers exhibited marked 
increase in solubility, dissolution rate and micromeritic properties (bulk 
density, flow property, compactability) compared with VAL. The SEM 
studies showed that the agglomerates posseeses a good spherical shape.    
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Introduction  
Aqueous solubility and dissolution are two of the 
crucial factors influencing drug absorption from the 
gastrointestinal tract. The solubility behavior of a 
drug is the key determinant of its oral bioavailability. 
Potential bioavailability problems are prevalent with 
extremely hydrophobic drugs due to erratic or 
incomplete absorption from GIT. Several methods 
have been used to increase the solubility and 
dissolution of poorly soluble substances like 
reduction in particle size, use of surfactants etc. but 
none of them have really been successful to improve 
solubility of poorly soluble drugs.  The solid 
dispersion  technique  for water-insoluble drugs is one  
 
of the most efficient methods to improve the 
dissolution rate, leading to high bioavailability. At 
present the solvent method and melting method are 
widely used in the preparation of solid dispersions [1-
3]. In general, subsequent grinding, sieving, mixing 
and granulation are necessary to produce the different 
desired formulations. The spherical agglomeration 
technique has been used as an efficient particle 
preparation technique [4-6]. Initially, spherical 
agglomeration technique was used to improve powder 
flowability and compressibility [7, 8]. Then polymers 
were introduced in this system to modify their release 
[9, 10]. Currently, this technique is used more 
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frequently for the solid dispersion preparation of 
water-insoluble drugs in order to improve their 
solubility, dissolution rate and simplify the 
manufacturing process [11]. Spherical agglomeration 
is carried out by following method, 1) Solvent 
Change System, 2) Quasi-emulsion solvent diffusion 
system (QEDS), 3) Ammonia diffusion system, 4) 
Neutralization technique [12]. Out of these 
techniques, the QEDS is most commonly used. This 
method employs three solvents 1) Good solvent: 
solvent that dissolves API, 2) Poor solvent: solvent in 
which API is insoluble, 3) Bridging liquid: solvent 
that dissolves API and is immiscible with poor 
solvent while miscible with good solvent. When 
bridging liquid plus good solvent containing API are 
poured into the poor solvent under agitation, quasi-
emulsion droplets of bridging liquid or good solvent 
form in the poor solvent and induces crystallization of 
the drug followed by agglomeration [13, 14].  
Valsartan (VAL) is a potent and specific competitive 
antagonist of angiotensin-II AT1- receptor [15, 16]. It 
is used orally for the treatment of hypertension and 
has low bioavailability. According to the 
Biopharmaceutical Classification Scheme [17], VAL 
is considered as a class II compound, i.e. water-
insoluble and highly permeable [18].  
 In the present study, to overcome the problems 
related to solubility, dissolution rate, flowability, and 
compressibility, the spherically agglomerated solid 
dispersions of VAL were prepared by QEDS, which 
is more convenient and is cheaper. In addition, 
incorporating hydrophilic polymers (Polyvinyl 
pyrrolidone, Hydroxypropyl β-cyclodextrin, 
Hydroxypropyl methylcellulose) during 
agglomeration imparted better solubility, dissolution 
rate, flowability and compressibility.   
 
Materials and methods  
Materials 
Valsartan was obtained as a gift sample from Lupin 
Research Park, Pune, India. Hydroxypropyl 
methylcellulose- 50 cps (HPMC), Polyvinyl 
pyrrolidone K-30 (PVP K-30), Hydroxypropyl β-
cyclodextrin were obtained as a gift sample from 
Signetchem, Mumbai, India. Aerosil 200 Pharma was 
obtained as gift sample from Evonik Degussa Group, 
France. Glyceryl monosterate, polyvinyl alcohol, 
acetone, and dichloromethane were purchased from 
Lobachemie, Mumbai, India. All other chemicals 
used were of analytical grade. 
 
Preparation of spherically agglomerated solid 
dispersion 
All spherical agglomerates were obtained by the quasi 
emulsion solvent diffusion method. At room 
temperature using distilled water (as external phase 
and poor solvent). The internal phase contained a 
good solvent (methanol) and a bridging liquid 
(dichloromethane). VAL (1 g) was added in the 
solution of methanol (3 mL), glyceryl monostearate 
(0.05 g), and polymer. A bridging liquid 
(dichloromethane 1 mL) was added to above mixture. 
Drug was crystallized by adding the above solution to 
a 250 mL capacity beaker containing a mixture of 
polyvinyl alcohol (0.25 g) and Aerosil 200 pharma 
(0.5 g) in distilled water (100 mL). The mixture was 
stirred continuously for a period of 0.5 h using a 
controlled speed mechanical stirrer (Remi Motors, 
India) at 800 rpm to obtained spherical agglomerated 
solid dispersions. As the good solvent diffused into 
the poor solvent, droplets gradually solidified and 
formed spherically agglomerated solid dispersion. 
The agglomerates were separated by filtration using 
Whatman filter paper (No.1) and dried in desiccator at 
room temperature. The amount of polymers was 
altered to get desired agglomerates. The composition 
is given in the table 1. 
 
Table 1. Composition of spherical agglomerates. 
 
Ingredients V-1 V-2 V-3 V-4 V-5 V-6 
Valsartan (g) 1 1 1 1 1 1 
Methanol (mL) 3 3 3 3 3 3 
PVP K-30 (mg) 50 100 -- -- -- -- 
HPβCD (mg) -- -- 50 100 -- -- 
HPMC (mg) -- -- -- -- 50 100 
Glyceryl 
Monostearate (mg) 50 50 50 50 50 50 
DCM (mL) 1 1 1 1 1 1 
Distilled Water 100 100 100 100 100 100 
PVA (mg) 250 250 250 250 250 250 
Aerosil 200 
Pharma (mg) 500 500 500 500 500 500 
Stirring speed 
(rpm) 800 800 800 800 800 800 
 
Infrared spectroscopy, differential scanning 
calorimetry (DSC) and Powder X-ray diffraction 
studies (PXRD) 
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The infrared (IR) spectra of powder VAL, and the 
agglomerates were recorded on an IR-
spectrophotometer (IRAFFINITY-1, Shimadzu, 
Japan). Differential scanning calorimetry (DSC) 
analysis was performed using a DSC 823 calorimeter 
(Mettler Toledo model) operated by star e software. 
Samples of VAL and its agglomerates were sealed in 
an aluminium crucible and heated at the rate of 10 0C 
min-1 up to 300 0C under a nitrogen atmosphere (40 
mL min-1). Powder X-ray diffraction patterns (XRD) 
of the pure drug and spherical agglomerates were 
monitored with an x-ray diffractometer (Panalytical 
Xpert pro MPD xrd machine) using copper as x-ray 
target, a voltage of 40 KV, a current of 30 mA and 
with 1.5404 Angstorm wavelength. Xcelerator RTMS 
with secondary monochromator was used as a 
detector. The samples were analyzed over 2θ range of 
7.02-59.980 with scanning step size of 0.020 (2θ) and 
scan step time of one second. 
 
Micromeritic properties  
The size of agglomerates was determined by 
microscopic method using stage and eyepiece 
micrometers. The shape of the agglomerates was 
observed under an optical microscope (60x 
magnification) attached to a computer. The loose bulk 
density (LBD) and tapped bulk density (TBD) of 
plain VAL and its spherical agglomerates were 
determined. Carr’s index and Hausner’s ratio were 
calculated using LBD and TBD values [19]. The 
angle of repose was accessed by the fixed funnel 
method [20]. 
 
Scanning electron microscopy 
The surface morphology of the agglomerates was 
accessed by scanning electron microscopy (SEM). 
The crystals were splutter coated with gold before 
scanning. 
 
Drug loading  
The drug loading efficiency of agglomerates was 
determined by dissolving 100 mg of crystals in 5 mL 
methanol and diluting further with distilled water 
(100 mL), followed by measuring the absorbance of 
appropriately diuted solution spectrophotometrically 
(PharmaSpec UV-1700, UV-Vis spectrophotometer, 
Shimadzu) at 250 nm. 
 
Solubility studies 
A quantity of crystals (about 100 mg) was shaken 
with 10 mL distilled water in stoppered conical flask 
at incubator shaker for 24 h at room temperature. The 
solution was then passed through a whatmann filter 
paper (No. 42) and amount of drug dissolved was 
analyzed spectrophotometrically. 
 
In vitro dissolution studies 
The in vitro dissolution studies were carried out using 
an 8 station USP 23 dissolution testing apparatus 
(Electrolab, India). The dissolution medium used was 
500 mL of distilled water [21] or 900 mL of 
Phosphate buffer pH 6.8 [22]. The dissolution 
medium was kept at in a thermostatically controlled 
water bath at 37±0.5 0C. The agglomerates and pure 
drug containing 80 mg of VAL were weighed and 
introduced into the dissolution medium. The medium 
was stirred at 50 rpm using paddle. The dissolution 
tests were carried out for 60 min. At predetermined 
time intervals 5 mL of samples were withdrawn and 
analyzed spectrophotometrically. At each time of 
withdrawal, 5 mL of fresh corresponding medium 
was replaced into the dissolution flask. The 
cumulative amount of drug release was calculated and 
plotted versus time. 
 
Dissolution efficiency studies 
The dissolution efficiency of the batches was 
calculated by the method mentioned by Khan [23]. It 
is defined as the area under the dissolution curve 
between time points t1 and t2 expressed as a 
percentage of the curve at maximum dissolution, 
y100, over the same time period or the area under the 
dissolution curve up to a certain time, t, (measured 
using trapezoidal rule) expressed as a percentage of 
the area of the rectangle described by 100% 
dissolution in the same time equation (01) [24].  
 
 
 (1) 
 
DE30 values were calculated from dissolution data and 
used to evaluate the dissolution rate. 
 
Statistical analysis 
The results were analyzed using the Graph Pad Instat 
Software (GPIS; version 5.0), and Microsoft Excel 
2007. One-way analysis of variance (ANOVA) and 
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Dunnett Multiple Comparisons Test were used to test 
statistical significance of the data. 
 
Results and discussion 
Formulation and development 
Spherically agglomerated solid dispersions of VAL 
were prepared by the quasi emulsion solvent diffusion 
method. A typical crystallization system involved a 
good solvent, poor solvent and bridging liquid. The 
selection of these solvents depends on the miscibility 
of the solvents and the solubility of the VAL in 
individual solvents. Since VAL is highly soluble in 
methanol, but poorly soluble in water. Also it is 
soluble in dichloromethane which is immiscible in 
water; therefore in the present study methanol, 
dichloromethane, and water were selected as good 
solvent, bridging liquid and poor solvent respectively. 
When the good solvent with drug and polymer is 
dispersed in the poor solvent quasi emulsion droplets 
produced. This is due to an increase in the interfacial 
tension between good and poor solvent. Then the 
good solvent diffuses gradually out of the emulsion 
droplet into the outer poor solvent phase. The 
counter-diffusion of the poor solvent into the droplets 
induces the crystallization of the drug within the 
droplet due to the decrease in solubility of the drug in 
the droplet containing the poor solvent. In the present 
study, the polymers (PVP-K30, HPβCD, HPMC) 
produced a high viscosity during the formation of 
coacervation droplets, and often caused the droplets 
to agglomerate into masses of irregular shapes and 
adhere to the propeller or the vessel wall. To 
overcome this Glyceryl monostearate, as an emulsion 
stabilizer and Aerosil 200 Pharma, as a dispersion 
agent were introduced into the formulation to avoid 
the coalescence of the droplets. It was also found that 
the addition of PVA to the aqueous dispersion 
medium prevented coalescence of the droplets. In the 
present study, distilled water containing PVA (0.25% 
w/v) was selected as a poor solvent and this result in 
the successful preparation of spherical agglomerates. 
 
IR, DSC, and PXRD studies 
The possible interaction between the drug and the 
carrier was studied by IR spectroscopy. The infrared 
spectra of VAL as well as its spherical agglomerates 
are presented in figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. IR spectra of (a) pure drug, (b) Spherical agglomerates V-2, (c) Spherical  agglomerates V-4, (d) 
Spherical agglomerates V-6. 
 
The principal IR peaks of pure VAL, and spherical 
agglomerates are shown in table 2. IR spectra of VAL  
 
showed characteristic peaks at 2966.52 (C-H str., -
CH3), 1734.01 and 1604.77 cm-1 (C=O str., Carboxyl 
307
Tapas et al. International Journal of Drug Delivery 2 (2010) 304-313 
 
 
and C=O str., amide, respectively). There were no 
considerable changes in the IR peaks of the spherical 
agglomerates when compared to pure VAL. If there is 
any strong interaction between drug and carrier, it 
often leads to identifiable changes in the IR profile 
and melting point of the drug. The results of IR 
spectra indicated the absence any well-defined 
interaction between VAL and PVP K-30, HPβCD, 
HPMC, Glyceryl monostearate, PVA, Aerosil in 
presence of methanol, dichloromethane, and water.  
The DSC patterns of pure VAL and its agglomerates 
are shown in figure 2. Pure VAL showed a single 
endotherm at 101.95 0C, which was ascribed to drug 
melting. This may indicated that the pure VAL is in 
its polymorph II form [25]. 
 
 
Table 2. Major IR peaks of pure valsartan, 
spherical agglomerates. 
 
Sample Major peaks 
(wave numbers, 
cm-1) 
Chemical moiety 
2966.52 C-H str., -CH3 
1734.01 C=O str., Carboxyl 
VAL 
1604.77 C=O str., amide 
2964.59 C-H str., -CH3 
1735.93 C=O str., Carboxyl 
V-2 
1612.49 C=O str., amide 
2962.66 C-H str., -CH3 
1732.08 C=O str., Carboxyl 
V-4 
1604.77 C=O str., amide 
2966.52 C-H str., -CH3 
1732.08 C=O str., Carboxyl 
V-6 
1606.7 C=O str., amide 
 
 
 
 
 
 
 
 
 
 
 
 
 
, d) 
Spherical agglomerates V-6. 
 
The DSC thermogram of spherical agglomerates with 
PVP K-30 showed two melting endotherms. The first 
one at 54.48 0C could be due to the melting of 
glyceryl monostearate and  the second one at 75.54 0C  
 
was ascribed to the melting of VAL which ma  get 
converted into its polymorph I form due to 
agglomeration process [26].  In case of DSC 
thermogram of spherical agglomerates with HPβ D a 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. DSC patterns of  a) valsartan, b) Spherical agglomerates V-2, c) Spherical agglomerates  V-4
y
C
(a) 
(c) (d) 
(b) 
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road endotherm at 50-80 0C was shown. It may be 
scribed to the melting of glyceryl monostearate and 
AL polymorph I. Also DSC thermogram of 
herical agglomerates with HPMC showed two 
arate and endotherm at 
2.57 C may be due to VAL polymorph I. Thus DSC 
studies conclude that the agglomerates show lower 
melting point melting points than pure drug but this 
may not be related to a change in the internal 
structure of the drug molecule. However change in 
the molecules and hence suggest the conversion of 
g effi
 
Density Density (%) 
’s 
Ratio 
b
a
V
sp
melting endotherms. Endotherm at 56.15 0C was due 
to melting of glyceryl monoste
0
the melting peak indicate a different arrangement of 
7 VAL polymorph II to polymorph I. 
ciency data for the agglomerates and pure druga. 
(LBD)         
(g mL-1) 
(TBD)       
(g mL-1) 
Angle of 
Repose (0) 
Particle Size 
(µm) 
Solubility in 
Water (mg 
mL-1) 
Drug 
Loading 
(%) 
 
Table 3. Micromeritics, solubility and drug loadin
Samples Loose Bulk Tapped Bulk Carr’s index Hausner
VAL 0.19 ± 0.02 0.30 ± 0.01 36.66 ± 2.63 1.57 ± 0.0 38.65 ± 1.65 40.45 ± 6.28 0.21 ± 0.25 100.0 ± 0.0 3 
V-1 0.23 ± 0.01b 0.25 ± 0.01 b 8.00 ± 1.51 b 1.08 ± 0.0 18.14 ± 1.78 b 144.4 ± 10.18 b 0.62 ± 0.35 b 97.0 ± 0.6 1 b 
V-2 0.23 ± 0.01 b 0.24 ± 0.02 b 3.67 ± 2.15 b 1.03 ± 0 19.29 ± 1.67 b 135.45 ± 9.21 b 0.89 ± 0.27 b 97.4 ± 0.5  .01 b 
V-3 0.30 ± 0.02 b 0.32 ± 0.01 b 6.25 ± 2.36 b 1.06 ± 0 14.32 ± 2.31 b 155.36 ± 12.10 b 0.92 ± 0.15 b 98.6 ± 0.6 .02 b 
V-4 0.31 ± 0.03 b 0.34 ± 0.01 b 8.82 ± 2.30 b 1.  0 13.13 ± 1.45 b 148 ± 7.54 b 1.23 ±.02 b  0.38 b 98.2 ± 0.3  09 ±
V-5 0.25 ± 0.01 b 0.27 ± 0.01 b 7.40 ± 2.69 b 1.08 ± 0.01 b 15.82 ± 1.65 b 218.89 ± 10.25 b 0.45 ± 0.63 b 94.1 ± 0.5  
V-   6 0.32 ± 0.02 b 0.34 ± 0.01 b 4.77 ± 3.12 b 1.05 ± 0.01 b 14.93 ± 1.30 b 373.40 ± 10.93 b 0.59 ± 0.54 b 95.5 ± 1.2
 
a Mean ± SD, n = 3.; b Significantly diffe nt compared to pure celecoxib (p < 0.05). 
 
The resu w  di tion patt  
VAL and ag d solid dispersions are 
n in X  o a
pho v f e
omer d  
tion   a
 resp L a  
ing L
omer l
modification and cha
which indicate a different arrangement of molecules 
 of crystals, w ed n 
optical microscope was spherical in all the p epared 
d  show  4
dis i
e
re
lts of the po
 spherical 
der X-ray
glomerate
ffrac ern of
show
r
 figure 3. P RD pattern f VAL indic tes its 
amo us nature. In estigation o  PXRD patt rns of 
aggl ates reveale  a number of changes in the 
loca of the peaks (appearance nd disappearance) 
with ect to VA . There is  difference in d-
spac between the PXRD spectra of VA  and 
aggl ated samp es referring to the habit 
nge in the intensity of peaks, 
hence confirming the development of a different 
polymorphic form. This observation further supports 
the DSC results, which indicated the conversion of 
VAL polymorph II to polymorph I. 
 
Micromeritic properties 
The mean particle diameter of agglomerates is shown 
in table 3. The pure drug exhibited a very small 
particle size (40.45 ± 6.28 µm, n = 3) whereas the size 
of prepared agglomerates was found between 135.45 
± 9.21 and 373.40 ± 10.93 µm, n = 3, which is 
significantly different from that of pure drug (p < 
0.05).  
The shape  the hen observ  using a
r
agglomerate  formulation n in figure  (a).  
 
Table 4. Drug release and solution eff ciency . a
 
Water Phosphat  Buffer 
pH 6.8 
Spherical 
Agglomerate
30
) 
s 
 DP60 
(%) 
DE
(%
 DP60 
(%) 
DE30 
(%) 
VAL 22.18 ± 3.07 ± 
0.19 0.01 
39.64 ± 
1.32 
14.38 ± 
0.26 
V-1 61.75 ± 11.70 ± 
23b 
56.26 ± 
1.13b 
28.76 ± 
0.66b 0.78 0.
V-2 74.29 ± 27
1.73b 
.66 ± 
0.86b 
85.59 ± 
1.01b  
46.86 ± 
0.67b 
V-3 65.77 ± 
0.75 
19.27 ± 
1.00b 
69.59 ± 
0.85b 
39.89 ± 
0.20b 
V-4 76.91 ± 
1.55b 
32.75 ± 
0.49b 
92.86 ± 
1.22b 
52.05 ± 
0.28b 
V-5 56.80 ± 
0.31 
10.31 ± 
0.27b 
63.93 ± 
0.51b 
36.48 ± 
0.61b 
V-6 69.31 ± 23.69 ± 81.97 ± 48.59 ± 
1.34b 0.68b 0.49b 0.32b 
 
DP60 – Percent drug release at 60 min.; DE30 – Dissolution 
Efficiency at 30 min.; a Mean ± SD, n = 3.; b Significantly 
different compared to pure valsartan (p < 0.05). 
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igure 3. X-ray d action spectra: a) pure drug b) Spherical agglomerates V-2, c) Spherical agglomerates  
-4, d) Spherical agglomerates V-6. 
he results of loose bulk density (LBD), tapped bulk 
ensity (TBD), Carr’s index, Hausner’s ratio, angle of 
pose are presented in table 3. These parameters 
ere used to assess the packability, flow and 
ompressibility properties of the agglomerates. The 
BD, TBD, Carr’s index, Hausner’s ratio and angle 
f repose values for pure drug VAL were 0.19 ± 0.02 
 mL-1( n = 3), 0.30 ± 0.01 g mL-1 (n = 3), 36.66 ± 
nd packability 
roperties. On the other hand, all prepared spherical 
compressibility of spherical agglomerates may be due 
to the sphericity, regular and larger size of crystals.  
 
Scanning electron microscopy  
The results of surface morphology studies are shown 
in figure 4. The SEM results revealed the spherical 
structure of agglomerates. The surface morphology 
studies also revealed that the agglomerates were 
compacted into spherical form. These photo-
micrographs show that the prepared agglomerates 
 
(a) (b) 
(c) 
(d)  
 
 
 
 
 
 
 
 
 
 
 
F iffr
V
 
T
d
re
w
c
L
o
g
2.63 % (n = 3), 1.57 ± 0.03 (n = 3), 38.65 ± 1.650 (n = 
3), respectively, indicating poor flow a
formed by very small crystals, which were closely 
p
agglomerates exhibited higher LBD (0.23 ± 0.01 to 
0.32 ± 0.02 g mL-1, n = 3) and TBD (0.24 ± 0.02 to 
0.34 ± 0.01 g mL-1, n = 3) values which indicate good 
packability. Also all the prepared agglomerates 
exhibited low Carr’s index, Hausner’s ratio and angle 
of repose values, indicating excellent flow properties 
and compressibility (Carr’s index: 3.67 ± 2.15 to 8.82 
± 2.30% , n = 3; Hausner’s ratio: 1.03 ± 0.01 to 1.05 
± 0.01, n = 3; angle of repose: 13.13 ± 1.450 to 19.29 
± 1.670, n = 3). The improved flowability and 
were spherical in shape which enabled them to flow 
very easily.  
 
Drug Loading and Solubility Studies 
The results of drug loading efficiency and aqueous 
solubility are shown in table 3. The drug loading of 
agglomerates was uniform among the different 
spherical agglomerates prepared and range from 94.1 
± 0.5 to 98.6 ± 0.6 % (n = 3), indicating negligible 
loss of drug during agglomeration process. The result 
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d 
gnificantly (p < 0.05), demonstrating that the 
ymers enhances the 
4. a) Optical micrograph herical agglomerat
pherical agglomerates containing PVP K-30 (V-2) at 200x, c) spherical agglomerates containing PVP K-30 
-2) at 500x, d) spherical agglomerates containing HPβCD (V-4) at 600x, e) spherical agglomerates 
ontaining  HPMC (V-6) at 100x, f) surface morphology of spherical agglomerates (V-4) at 1000x. 
n vitro dissolution studies 
he results of in vitro dissolution studies are shown in 
gure 5 and table 4. Pure VAL exhibited less release 
t the end of 60 min in water (22.18 ± 0.19%, n = 3) 
nd in phosphate buffer pH 6.8 (39.64 ± 1.32%, n = 
); spherically agglomerated solid dispersion 
hosphate buffer pH 6.8 at the end 60 min. The 
in (DE30) for pure drug 
 
(n = 3) in water and 52.05 ± 0.28% (n = 3) in 
phosphate buffer pH 6.8 respectively. The results 
revealed that the spherically agglomerated solid 
dispersion showed significant increase (p < 0.05) in 
drug release compared to the pure drug. Among the 
ttributed to 
deposition of polymer onto the recrystallized drug 
of solubility studies indicate that pure VAL possesses 
a very low solubility in water (0.21 ± 0.25 mg mL-1, n 
= 3); the drug solubility from crystals increase
si
incorporation of hydrophilic pol
drug solubility. Also as the concentration of 
hydrophilic polymer increased, the drug solubility 
also increased. Amongst the hydrophilic polymers 
used HPβCD spherical agglomerates shows 
maximum solubility (1.23 ± 0.38 mg mL-1, n = 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  of sp es (50x), Scanning electron micrographs of: b) 
s
(V
c
 
I
T
fi
a
a
3
improved the dissolution rate of VAL in water and 
phosphate buffer pH 6.8 as dissolution medium. The 
agglomerates (V-4) released 76.91 ± 1.55% (n = 3) 
drug in water and 92.86 ± 1.22% (n = 3) drug in 
different hydrophilic polymer tested, HPβCD showed 
better effect on solubility and dissolution rate 
compared to other polymers. The increase in the 
dissolution rate of agglomerates could be a
p
dissolution efficiency at 30 m
was 3.07 ±0.01% (n = 3) and 14.38 ± 0.26 (n = 3) in 
water and phosphate buffer pH 6.8 respectively, 
whereas  for  agglomerates  (V-4) was 32.75 ± 0.49%  
surface and better wettability of the spherically 
agglomerated solid dispersions. The percent drug 
release from different agglomerates was increased in 
the following order: HPβCD>PVP-K30>HPMC.  
(a) (b) (c) 
(d) (e) (f) 
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Figure 5. Dissolution profile of pure drug and 
agglomerates: (a) water, (b) Phosphate Buffer pH 
6.8. (n = 3). 
 
Conclusion 
The present study shows that spherically 
agglomerated solid dispersion of VAL prepared with 
HPβCD, PVP K-30, and HPMC exhibited improved 
solubility and dissolution rate in addition to 
im
technique may be applicable for producing oral solid 
dosage forms of VAL with improved dissolution rate 
with improving physicochemical and micromeritic 
roperties. p
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